Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pedea versus Iranian intravenous ibuprofen for patent ductus arteriosus closure in preterm infants
IRCT20140519017756N48Phase 3Completed
- Sponsor
- Vice Chancellor for Research, Birjand University of Medical Sciences
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ibuprofen in patent ductus arteriosus (PDA) (2 arms), sponsored by Vice Chancellor for Research, Birjand University of Medical Sciences. Primary endpoint: Ductus arteriosus closure. Started Jun 2023; status: completed.
02
Drugs
ibuprofen
03
Conditions
patent ductus arteriosus (PDA)
Beyond the preview
Go deeper on IRCT20140519017756N48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20140519017756N48.